TY - JOUR
T1 - Applications of Cardiac Computed Tomography in the Cardio-Oncology Population
AU - Layoun, Michael E.
AU - Yang, Eric H.
AU - Herrmann, Joerg
AU - Iliescu, Cezar A.
AU - Lopez-Mattei, Juan C.
AU - Marmagkiolis, Kostas
AU - Budoff, Matthew J.
AU - Ferencik, Maros
N1 - Funding Information:
Juan C. Lopez-Mattei declares that he has no conflict of interest. Kostas Marmagkiolis declares that he has no conflict of interest. Matthew J. Budoff has received research funding from General Electric. Maros Ferencik has received research funding from the American Heart Association and the National Institutes of Health.
Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - The increased risk for cardiovascular events in aging cancer survivors and those undergoing certain chemotherapeutic treatments has raised concern for more rigorous screening and surveillance methods above that of the general population. At this time, there are limited guidelines for how to best manage this vulnerable cohort. Questions regarding timing of screening, choice of imaging modality and risk reduction strategies—especially in those patients with known atherosclerotic disease—remain to be elucidated. Over a decade of case series, retrospective studies and clinical trials have shed light on the evolving role of cardiac computed tomography (CT) in this population, of which there is a relative paucity of data regarding its potential utility in the specific cardio-oncology population. Focusing on ability of cardiac CT to evaluate multiple cardiac and vascular structures, provide diagnostic and prognostic information, as well as assist interventional and surgical colleagues in surgical/percutaneous valve replacement and revascularization strategies is the premise for this review.
AB - The increased risk for cardiovascular events in aging cancer survivors and those undergoing certain chemotherapeutic treatments has raised concern for more rigorous screening and surveillance methods above that of the general population. At this time, there are limited guidelines for how to best manage this vulnerable cohort. Questions regarding timing of screening, choice of imaging modality and risk reduction strategies—especially in those patients with known atherosclerotic disease—remain to be elucidated. Over a decade of case series, retrospective studies and clinical trials have shed light on the evolving role of cardiac computed tomography (CT) in this population, of which there is a relative paucity of data regarding its potential utility in the specific cardio-oncology population. Focusing on ability of cardiac CT to evaluate multiple cardiac and vascular structures, provide diagnostic and prognostic information, as well as assist interventional and surgical colleagues in surgical/percutaneous valve replacement and revascularization strategies is the premise for this review.
KW - Cardiac computed tomography angiography
KW - Cardiotoxicity
KW - Coronary artery calcium score
KW - Radiation-induced valvulopathy
KW - Vasculotoxicity
UR - http://www.scopus.com/inward/record.url?scp=85065410028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065410028&partnerID=8YFLogxK
U2 - 10.1007/s11864-019-0645-2
DO - 10.1007/s11864-019-0645-2
M3 - Review article
C2 - 31056717
AN - SCOPUS:85065410028
SN - 1527-2729
VL - 20
JO - Current treatment options in oncology
JF - Current treatment options in oncology
IS - 6
M1 - 47
ER -